TY - JOUR
T1 - Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer
T2 - Findings from CALGB 89803
AU - Meyerhardt, Jeffrey A.
AU - Heseltine, Denise
AU - Niedzwiecki, Donna
AU - Hollis, Donna
AU - Saltz, Leonard B.
AU - Mayer, Robert J.
AU - Thomas, James
AU - Nelson, Heidi
AU - Whittom, Renaud
AU - Hantel, Alexander
AU - Schilsky, Richard L.
AU - Fuchs, Charles S.
PY - 2006/8/1
Y1 - 2006/8/1
N2 - Purpose: Regular physical activity reduces the risk of developing colon cancer, however, its influence on patients with established disease is unknown. Patients and Methods: We conducted a prospective observational study of 832 patients with stage III colon cancer enrolled in a randomized adjuvant chemotherapy trial. Patients reported on various recreational physical activities approximately 6 months after completion of therapy and were observed for recurrence or death. To minimize bias by occult recurrence, we excluded patients who experienced recurrence or died within 90 days of their physical activity assessment. Results: Compared with patients engaged in less than three metabolic equivalent task (MET) -hours per week of physical activity, the adjusted hazard ratio for disease-free survival was 0.51 (95% CI, 0.26 to 0.97) for 18 to 26.9 MET-hours per week and 0.55 (95% CI, 0.33 to 0.91) for 27 or more MET-hours per week. The adjusted P for trend was .01. Postdiagnosis activity was associated with similar improvements in recurrence-free survival (P for trend = .03) and overall survival (P for trend = .01). The benefit associated with physical activity was not significantly modified by sex, body mass index, number of positive lymph nodes, age, baseline performance status, or chemotherapy received. Moreover, the benefit remained unchanged even after excluding participants who developed cancer recurrence or died within 6 months of activity assessment. Conclusion: Beyond surgical resection and postoperative adjuvant chemotherapy for stage III colon cancer, for patients who survive and are recurrence free approximately 6 months after adjuvant chemotherapy, physical activity appears to reduce the risk of cancer recurrence and mortality.
AB - Purpose: Regular physical activity reduces the risk of developing colon cancer, however, its influence on patients with established disease is unknown. Patients and Methods: We conducted a prospective observational study of 832 patients with stage III colon cancer enrolled in a randomized adjuvant chemotherapy trial. Patients reported on various recreational physical activities approximately 6 months after completion of therapy and were observed for recurrence or death. To minimize bias by occult recurrence, we excluded patients who experienced recurrence or died within 90 days of their physical activity assessment. Results: Compared with patients engaged in less than three metabolic equivalent task (MET) -hours per week of physical activity, the adjusted hazard ratio for disease-free survival was 0.51 (95% CI, 0.26 to 0.97) for 18 to 26.9 MET-hours per week and 0.55 (95% CI, 0.33 to 0.91) for 27 or more MET-hours per week. The adjusted P for trend was .01. Postdiagnosis activity was associated with similar improvements in recurrence-free survival (P for trend = .03) and overall survival (P for trend = .01). The benefit associated with physical activity was not significantly modified by sex, body mass index, number of positive lymph nodes, age, baseline performance status, or chemotherapy received. Moreover, the benefit remained unchanged even after excluding participants who developed cancer recurrence or died within 6 months of activity assessment. Conclusion: Beyond surgical resection and postoperative adjuvant chemotherapy for stage III colon cancer, for patients who survive and are recurrence free approximately 6 months after adjuvant chemotherapy, physical activity appears to reduce the risk of cancer recurrence and mortality.
UR - http://www.scopus.com/inward/record.url?scp=33747075458&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33747075458&partnerID=8YFLogxK
U2 - 10.1200/JCO.2006.06.0863
DO - 10.1200/JCO.2006.06.0863
M3 - Article
C2 - 16822843
AN - SCOPUS:33747075458
SN - 0732-183X
VL - 24
SP - 3535
EP - 3541
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 22
ER -